Melanoma Risk Identification via SLC45A2 and MC1R Polymorphism Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing skin cancer, particularly melanoma, are inadequate in identifying individuals with the greatest predisposition due to the involvement of multiple genetic factors, with existing genetic markers not fully capturing the risk associated with skin cancer susceptibility.
Innovation Solution
The method involves analyzing specific gene polymorphisms, such as SLC45A2 374F and MC1R variants, in biological samples to identify subjects at increased risk of melanoma, using techniques like SNP detection and gene expression analysis to determine the presence of risk or protective alleles independently of pigmentation characteristics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used for skin cancer, then the diagnosis process is simple, but the ability to identify individuals with the greatest predisposition is insufficient
Solution Approach 1:
The diagnostic approach segments the complexity by focusing on specific gene polymorphisms (SLC45A2 and MC1R) rather than analyzing all genetic factors simultaneously. This selective segmentation allows for improved identification accuracy while managing the complexity through targeted analysis of key risk markers.
Solution Approach 2:
The method performs preliminary genetic screening to identify individuals with risk alleles before clinical diagnosis is needed. By detecting SLC45A2 and MC1R polymorphisms in advance, the system enables early prioritization of monitoring for high-risk individuals, improving measurement precision without requiring complex real-time diagnostic systems.
2Reliability
If multiple genetic factors are considered for melanoma risk, then the risk assessment becomes more accurate, but the difficulty of detection and measurement increases
Solution Approach 1:
The invention extracts and focuses on the two most significant genetic factors (SLC45A2 and MC1R polymorphisms) from the complex array of multiple genetic factors. By isolating these key markers, the method achieves reliable risk assessment while simplifying the detection process, avoiding the need to measure all possible genetic variants.
Solution Approach 2:
The approach changes the measurement parameters by transitioning from analyzing multiple genetic factors to measuring specific polymorphic alleles (374F vs 374L for SLC45A2, and various MC1R variants). This parameter simplification maintains reliability by focusing on the most impactful genetic markers while reducing the difficulty of detection.
3Loss of information
If existing genetic markers are used, then the testing process is straightforward, but the risk associated with skin cancer susceptibility is not fully captured
Solution Approach 1:
The method merges the assessment of multiple risk factors (SLC45A2 and MC1R polymorphisms, clinical parameters, and environmental factors) into a comprehensive risk evaluation system. This combination captures complete risk information while maintaining ease of manufacture by integrating these factors into a unified diagnostic workflow rather than requiring separate complex testing procedures.
Data Source
AI summary
The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO: 1), and/or analysing the expression of the MATP/SLC45A2 gene; to the use, for preparing a composition for the treatment and/or prevention of a skin cancer in an individual, of a compound which specifically increases the expression of the MATP/SLC45A2 gene in a skin cell; and to a method for the selection, in vitro, of a compound capable of being of use in the treatment of skin cancer.